EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report

Sisi Deng, Huan Wang, Shuguang Chen, Minmin Kong, Xianjie Yang, Zhiqiang Song, Qiquan Chen

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.111137 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Sisi Deng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subcutaneous immunotherapy (SCIT) and dupilumab are important treatments for patients with moderate to severe atopic dermatitis (AD). However, in clinical practice, poor response to allergen immunotherapy (AIT) or dupilumab has been observed in some patients. It is unknown whether combining dupilumab and SCIT can improve treatment responses in patients with moderate to severe AD that is resistant to dupilumab or SCIT monotherapy. This single-centre, retrospective, observational, real-world study evaluated the efficacy and safety of dupilumab and SCIT for refractory moderate to severe AD. The data of ten patients with moderate to severe atopic dermatitis who were treated with dupilumab and SCIT were retrospectively analysed. The scoring atopic dermatitis (SCORAD) score, numerical rating scale (NRS), and atopic dermatitis control test (ADCT) scores and eosinophil and total IgE levels before and after add-on therapy were compared and analysed. The SCORAD, NRS, and ADCT scores decreased significantly at four and 12 weeks after the initiation of add-on therapy and plateaued during maintenance treatment. The eosinophil and total IgE levels were not significantly different before and after add-on therapy. No serious adverse reactions were reported in any patient during add-on therapy. This study indicates that the combination of dupilumab and SCIT safely improves the treatment response of patients with moderate to severe AD who are resistant to dupilumab or SCIT monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansRetrospective StudiesTreatment OutcomeInjections, SubcutaneousDesensitization, ImmunologicImmunoglobulin ESeverity of Illness IndexDouble-Blind MethodAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Atopic dermatitisDupilumabSubcutaneous immunotherapy

Substanzen

Immunoglobulin EdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China.
  • School of Medicine, Chongqing University, Chongqing 400038, China.
  • Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Electronic address: drsongzq@hotmail.com.
  • Department of Dermatology, Southwest Hospital, Amy Medical University, Chongqing, China. Electronic address: chenqq0548@163.com.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Deng, S., Wang, H., Chen, S., Kong, M., Yang, X., Song, Z., & Chen, Q. (2023). Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.111137

Vancouver

Deng S, Wang H, Chen S, Kong M, Yang X, Song Z, et al. Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.111137

BibTeX
@article{Deng2023,
  author = {Deng, Sisi and Wang, Huan and Chen, Shuguang and Kong, Minmin and Yang, Xianjie and Song, Zhiqiang and Chen, Qiquan},
  title = {Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.111137}
}
Kostenlos starten →